SCHEMBL22491229

SCHEMBL22491229

C=CCOc1cccc(CC(NC(CC(C)C)C(=O)OC(=O)C(CC(C)C)NC(Cc2cccc(OCc3cc(F)cc(F)c3)c2)C(=O)O)C(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.43
ACE P12821 1/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
GPR34 Q9UPC5 4/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
BCHE P06276 1/20 0.40
GPR132 Q9UNW8 3/20 0.39
CTSK P43235 1/20 0.38
FOLH1 Q04609 1/20 0.38
ALDH1A1 P00352 1/20 0.37
NR4A2 P43354 1/20 0.37
CYSLTR2 Q9NS75 1/20 0.37
CYSLTR1 Q9Y271 1/20 0.37
MAOB P27338 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22491225 0.95 MME (0.46) MMEACECPA1ACE2GPR34
SCHEMBL5869327 0.87 MME (0.52) MMEACECPA1ACE2GPR34
SCHEMBL8249399 0.87 MME (0.52) MMEACECPA1ACE2GPR34
SCHEMBL5870373 0.85 KDM4E (0.47) MMEACECPA1ACE2KDM4E
SCHEMBL5869511 0.85 KDM4E (0.47) MMEACECPA1ACE2KDM4E
SCHEMBL8249827 0.78 MME (0.62) MMEACECPA1ACE2GPR34
SCHEMBL5869314 0.77 MME (0.53) MMEACECPA1ACE2GPR34
SCHEMBL8255762 0.77 MME (0.53) MMEACECPA1ACE2GPR34
SCHEMBL5869311 0.76 ACE2 (0.52) MMEACECPA1ACE2GPR34
SCHEMBL8250026 0.76 ACE2 (0.52) MMEACECPA1ACE2GPR34

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11337909-B2 Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) 2022-05-24 US disclosed
US-20200360258-A1 METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) 2020-11-19 US disclosed
EP-3717077-A1 METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360258-A1 METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION ACE, ACE2, TYR MME 44/4885ACE 1/4885CPA1 99/4885
US-11337909-B2 Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation ACE, ACE2, TYR MME 44/4885ACE 1/4885CPA1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.